ESMO: New Trodelvy breast, bladder cancer data show why Gilead’s going big for Immunomedics

Compared with the spate of multibillion-dollar buyouts last year, biopharma M&A has been relatively quiet in 2020—until last week, when Gilead Sciences surprised the market with its $ 21 billion purchase of Immunomedics. Now, two sets of new cancer data from Immunomedics’ first-in-class antibody-drug conjugate Trodelvy offer a glimpse into why Gilead paid such big money… Read More »

Intestinal Organoids Mimic Human Gut

Researchers at Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland have developed a mini intestine on a chip that closely mimics the morphology and cellular composition of the small intestine. The device could be useful for advancing personalized medicine, drug screening, and even paving the way for researchers to grow new tissues and organs in… Read More »

In ‘Power Grab,’ Health Secretary Azar Asserts Authority Over F.D.A.

In a stunning declaration of authority, Alex M. Azar II, the secretary of health and human services, this week barred the nation’s health agencies, including the Food and Drug Administration, from signing any new rules regarding the nation’s foods, medicines, medical devices and other products, including vaccines. Going forward, Mr. Azar wrote in a Sept.… Read More »